GeneDx (NASDAQ:WGS) Releases Earnings Results, Beats Expectations By $0.66 EPS

GeneDx (NASDAQ:WGS) announced its quarterly earnings results on Tuesday. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.66, Zacks reports. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. GeneDx updated its FY 2025 guidance to EPS.

GeneDx Trading Up 47.7 %

Shares of WGS opened at $112.76 on Wednesday. The firm has a fifty day simple moving average of $77.30 and a two-hundred day simple moving average of $61.79. GeneDx has a twelve month low of $4.61 and a twelve month high of $113.92. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27.

Insider Transactions at GeneDx

In other GeneDx news, CFO Kevin Feeley sold 12,019 shares of the firm’s stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $73.76, for a total transaction of $886,521.44. Following the completion of the sale, the chief financial officer now directly owns 32,932 shares in the company, valued at approximately $2,429,064.32. This trade represents a 26.74 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Katherine Stueland sold 1,657 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $78.48, for a total transaction of $130,041.36. Following the sale, the chief executive officer now owns 3,937 shares of the company’s stock, valued at approximately $308,975.76. This represents a 29.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 139,603 shares of company stock valued at $12,223,041. Company insiders own 27.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on WGS shares. TD Cowen upped their price target on shares of GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday, January 7th. The Goldman Sachs Group upped their target price on shares of GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Craig Hallum increased their price target on shares of GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Finally, Wells Fargo & Company upped their price objective on shares of GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 30th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $70.67.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.